{
    "symbol": "PAVM",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-12 21:19:10",
    "content": " With regard to revenue, PAVmed recognized approximately $200,000 revenues related to the EsoGuard for the first quarter ended March 31, despite the negative gross profit for the last quarter, which reflects the initial test center startup related cost at modest volumes incremental gross margins can be around 90% and contribution margins north of 60%. For the three months ended March 31, 2021 PAVmed's consolidated operating expenses were $19.3 million, compared to $8.1 million during the same period in 2021 with 83% of the net increase attributable to compensation related to headcount increases stock-based compensation, consulting services and development costs, particularly in the clinical activities and outside professional services."
}